About fortress biotech inc. - FBIO
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.
FBIO At a Glance
Fortress Biotech, Inc.
1111 Kane Concourse
Bay Harbor Islands, Florida 33154
| Phone | 1-781-652-4500 | Revenue | 63.26M | |
| Industry | Pharmaceuticals: Major | Net Income | 6.82M | |
| Sector | Health Technology | 2025 Sales Growth | 9.687% | |
| Fiscal Year-end | 12 / 2026 | Employees | 78 | |
| View SEC Filings |
FBIO Valuation
| P/E Current | 1.024 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.614 |
| Price to Book Ratio | 2.302 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.608 |
| Enterprise Value to Sales | 1.617 |
| Total Debt to Enterprise Value | 0.657 |
FBIO Efficiency
| Revenue/Employee | 811,051.282 |
| Income Per Employee | 87,371.795 |
| Receivables Turnover | 2.113 |
| Total Asset Turnover | 0.384 |
FBIO Liquidity
| Current Ratio | 2.49 |
| Quick Ratio | 2.296 |
| Cash Ratio | 1.596 |
FBIO Profitability
| Gross Margin | 59.557 |
| Operating Margin | -111.00 |
| Pretax Margin | -53.01 |
| Net Margin | 10.773 |
| Return on Assets | 4.133 |
| Return on Equity | 18.772 |
| Return on Total Capital | 5.82 |
| Return on Invested Capital | 6.478 |
FBIO Capital Structure
| Total Debt to Total Equity | 134.774 |
| Total Debt to Total Capital | 57.406 |
| Total Debt to Total Assets | 36.226 |
| Long-Term Debt to Equity | 130.517 |
| Long-Term Debt to Total Capital | 55.589 |